DK2846809T3 - Behandling af myelosuppression - Google Patents

Behandling af myelosuppression Download PDF

Info

Publication number
DK2846809T3
DK2846809T3 DK13787651.2T DK13787651T DK2846809T3 DK 2846809 T3 DK2846809 T3 DK 2846809T3 DK 13787651 T DK13787651 T DK 13787651T DK 2846809 T3 DK2846809 T3 DK 2846809T3
Authority
DK
Denmark
Prior art keywords
myelosuppression
treatment
Prior art date
Application number
DK13787651.2T
Other languages
English (en)
Inventor
Stephen Marcus
Original Assignee
Cantex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantex Pharmaceuticals Inc filed Critical Cantex Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2846809T3 publication Critical patent/DK2846809T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DK13787651.2T 2012-05-09 2013-03-13 Behandling af myelosuppression DK2846809T3 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201261644623P 2012-05-09 2012-05-09
US201261644556P 2012-05-09 2012-05-09
US201261648043P 2012-05-16 2012-05-16
US201261653362P 2012-05-30 2012-05-30
US201261664611P 2012-06-26 2012-06-26
US201261668709P 2012-07-06 2012-07-06
US201261678053P 2012-07-31 2012-07-31
US201261702207P 2012-09-17 2012-09-17
US201261724836P 2012-11-09 2012-11-09
PCT/US2013/031053 WO2013169355A1 (en) 2012-05-09 2013-03-13 Treatment of myelosuppression

Publications (1)

Publication Number Publication Date
DK2846809T3 true DK2846809T3 (da) 2021-01-18

Family

ID=49549076

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13787651.2T DK2846809T3 (da) 2012-05-09 2013-03-13 Behandling af myelosuppression

Country Status (21)

Country Link
US (6) US9271999B2 (da)
EP (2) EP2846809B1 (da)
JP (3) JP6177885B2 (da)
KR (2) KR102452803B1 (da)
CN (3) CN113521093A (da)
AU (1) AU2013260101B2 (da)
BR (1) BR112014028094B1 (da)
CA (2) CA3122808A1 (da)
CL (2) CL2014003017A1 (da)
DK (1) DK2846809T3 (da)
EA (1) EA029382B1 (da)
ES (1) ES2848050T3 (da)
HK (1) HK1207574A1 (da)
HU (1) HUE053247T2 (da)
IL (1) IL235593B (da)
LT (1) LT2846809T (da)
MX (2) MX370567B (da)
PL (1) PL2846809T3 (da)
PT (1) PT2846809T (da)
SG (3) SG11201407340YA (da)
WO (1) WO2013169355A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407340YA (en) 2012-05-09 2014-12-30 Cantex Pharmaceuticals Inc Treatment of myelosuppression
SG11201603081WA (en) * 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
RU2753543C1 (ru) 2016-02-08 2021-08-17 Бейондспринг Фармасьютикалс, Инк. Композиции, содержащие тукаресол или его аналоги
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
CN107569486A (zh) * 2017-08-23 2018-01-12 北京京佑奇康生物科技有限公司 孟鲁司特钠治疗血小板减少症的新用途
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
SG11202006985TA (en) * 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
MX2021008928A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
US20230023092A1 (en) 2019-04-17 2023-01-26 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US20220305048A1 (en) * 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
EP4058018A4 (en) * 2019-11-13 2023-06-21 Taiho Pharmaceutical Co., Ltd. METHODS OF TREATMENT OF LSD1-RELATED DISEASES AND DISORDERS USING LSD1 INHIBITORS
WO2021207697A1 (en) 2020-04-10 2021-10-14 Cantex Pharmaceuticals, Inc. Treatment of acute lung injury
EP4182452A1 (en) 2020-07-14 2023-05-24 Optimvia, LLC Methods for synthesizing non-anticoagulant heparan sulfate
KR20230058289A (ko) 2021-10-21 2023-05-03 숙명여자대학교산학협력단 혈액암 치료를 위한 글리세오플빈 병용요법

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
FR2553287B1 (fr) 1983-10-18 1986-09-12 Choay Sa Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
DE3422518A1 (de) 1984-06-16 1985-12-19 B. Braun Melsungen Ag, 3508 Melsungen Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen
FR2584606A1 (fr) 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5399493A (en) 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
AU7681091A (en) 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5306724A (en) 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
GB2270841A (en) 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
WO1994018989A1 (en) 1993-02-22 1994-09-01 Cavalier Pharmaceuticals, Inc. Use of heparin to inhibit interleukin-8
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5994318A (en) 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5840707A (en) 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5990097A (en) 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
US6154502A (en) 1996-08-22 2000-11-28 Intel Corporation Signal constellation slicer
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
CN1159061C (zh) 1997-02-15 2004-07-28 千年药物公司 通过nf-kappab的抑制治疗梗塞
WO1998053852A1 (en) 1997-05-30 1998-12-03 Arch Development Corporation P-selectin translocation to vascular epithelial lumen by ionizing radiation
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
ATE320263T1 (de) 1998-11-13 2006-04-15 Lilly Co Eli Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6514502B1 (en) 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells
WO2001019376A2 (en) 1999-09-13 2001-03-22 Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
PT1385498E (pt) * 2001-04-18 2007-12-14 Prometic Biosciences Inc Ácidos gordos como factores de sobrevivência e activação de neutrófilos
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
AU2003293122A1 (en) 2002-11-27 2004-06-23 Massachusetts Institute Of Technology Methods for synthesizing polysaccharides
US20040180812A1 (en) 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
AU2004251599A1 (en) 2003-05-20 2005-01-06 Transtech Pharma, Inc. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
US7538096B2 (en) 2004-03-16 2009-05-26 The General Hospital Corporation Treatment and prevention of abnormal cellular proliferation
EP1744764B1 (en) * 2004-04-22 2012-05-30 Celator Pharmaceuticals, Inc. Liposomal formulations of anthracycline agents and cytidine analogs
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) * 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US7468358B2 (en) 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP2006076968A (ja) 2004-09-10 2006-03-23 Seikagaku Kogyo Co Ltd 生理活性分子含有架橋ヘパリンゲル組成物
WO2007014049A2 (en) 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compositions and selectin inhibition
WO2007019554A2 (en) 2005-08-08 2007-02-15 Momenta Pharmaceuticals, Inc. Polysaccharides for delivery of active agents
WO2007040105A1 (ja) 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法
KR20080080641A (ko) 2005-12-16 2008-09-04 디엔피 캐나다 인코포레이티드 고지혈증용 키틴 유도체
WO2007115372A1 (en) 2006-04-10 2007-10-18 Monash University A method of modulating beta-amyloid peptide production
US20100003226A1 (en) 2006-07-26 2010-01-07 Intrexon Corporation Methods and Compositions for Treating Disease
EP2061504A4 (en) 2006-09-20 2010-01-27 Univ Johns Hopkins COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES
WO2008106584A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
EP2170354A1 (en) 2007-07-23 2010-04-07 University of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009117677A2 (en) 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
US8476249B2 (en) * 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
EP2482903B1 (en) 2009-09-29 2018-11-14 Vectura GmbH Improved method for treatment of patients with cystic fibrosis
JP2013522172A (ja) 2010-03-12 2013-06-13 ジ オーストラリアン ナショナル ユニバーシティ ヘパラン硫酸補充療法
NZ602992A (en) * 2010-03-24 2014-11-28 Servier Lab Prophylaxis of colorectal and gastrointestinal cancer
EP3153173A1 (en) 2010-06-28 2017-04-12 Stemtech International, Inc. Methods and compositions for enhancing stem cell mobilization
JP2014503597A (ja) * 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
WO2012106379A1 (en) 2011-02-01 2012-08-09 Paringenix, Inc. Sensitization of cancer cells to treatment
WO2013016181A1 (en) 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
EP2844278A4 (en) 2012-05-01 2015-11-04 Univ Duke COMPOSITIONS AND METHODS FOR USING HEPARAN SULFATE AS A BIOLOGICAL MARKER FOR TRANSPLANT REJECTION
SG11201407340YA (en) 2012-05-09 2014-12-30 Cantex Pharmaceuticals Inc Treatment of myelosuppression
JP2016516672A (ja) 2013-02-28 2016-06-09 プレジデント アンド フェローズ オブ ハーバード カレッジ 幹細胞を動員するための方法および組成物
SG11201603081WA (en) 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
WO2015061604A1 (en) 2013-10-24 2015-04-30 Thomas Kennedy Treating bacterial infections of the lung
WO2015142924A1 (en) 2014-03-17 2015-09-24 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2016133907A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
US20170106011A1 (en) 2015-10-20 2017-04-20 Cantex Pharmaceuticals, Inc. Methods of treating traumatic brain injury and sequelae
WO2017123549A1 (en) 2016-01-11 2017-07-20 Cantex Pharmaceuticals, Inc. Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids

Also Published As

Publication number Publication date
IL235593A0 (en) 2015-01-29
JP2017105850A (ja) 2017-06-15
AU2013260101B2 (en) 2016-10-27
JP6177885B2 (ja) 2017-08-09
PT2846809T (pt) 2021-02-05
CN104411316A (zh) 2015-03-11
WO2013169355A1 (en) 2013-11-14
KR102452803B1 (ko) 2022-10-07
KR20200118510A (ko) 2020-10-15
SG10201603059YA (en) 2016-05-30
CN108498532B (zh) 2021-07-23
BR112014028094A2 (pt) 2020-06-30
IL235593B (en) 2019-06-30
US20220354882A1 (en) 2022-11-10
EP2846809A1 (en) 2015-03-18
AU2013260101A1 (en) 2014-12-18
CN113521093A (zh) 2021-10-22
EA201492052A1 (ru) 2015-08-31
US20130323230A1 (en) 2013-12-05
EA029382B1 (ru) 2018-03-30
EP2846809A4 (en) 2015-12-30
KR20150023361A (ko) 2015-03-05
MX370567B (es) 2019-12-17
ES2848050T3 (es) 2021-08-05
CN108498532A (zh) 2018-09-07
US20130303481A1 (en) 2013-11-14
US11229664B2 (en) 2022-01-25
JP6448694B2 (ja) 2019-01-09
LT2846809T (lt) 2021-01-25
SG10201914117QA (en) 2020-02-27
US20160213706A1 (en) 2016-07-28
US9271999B2 (en) 2016-03-01
US20200038431A1 (en) 2020-02-06
JP6726252B2 (ja) 2020-07-22
JP2019026647A (ja) 2019-02-21
SG11201407340YA (en) 2014-12-30
MX2019009437A (es) 2019-10-02
CL2014003017A1 (es) 2015-07-10
HK1207574A1 (en) 2016-02-05
PL2846809T3 (pl) 2021-07-26
CA2872855A1 (en) 2013-11-14
EP3785720A1 (en) 2021-03-03
JP2015521176A (ja) 2015-07-27
CA3122808A1 (en) 2013-11-14
HUE053247T2 (hu) 2021-06-28
KR102165348B1 (ko) 2020-10-14
EP2846809B1 (en) 2020-10-14
US8734804B2 (en) 2014-05-27
MX2014013633A (es) 2015-07-06
CL2021000008A1 (es) 2021-06-11
CN104411316B (zh) 2018-05-01
BR112014028094B1 (pt) 2022-03-03
US20180296590A1 (en) 2018-10-18
CA2872855C (en) 2021-07-27

Similar Documents

Publication Publication Date Title
DK2846809T3 (da) Behandling af myelosuppression
DK2968208T3 (da) Behandling af kataplexi
DK2785349T3 (da) Kombinationsbehandling af cancer
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK2717941T3 (da) Behandling af cancer
AR092198A1 (es) Derivados de pirazolopirimidinas
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK2668967T3 (da) Implantat
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
BR112014013850A2 (pt) conjunto de prateleiras
DK2906580T3 (da) Behandling af amyotrofisk lateral sklerose
DK2925338T3 (da) Frysetørret formulering af tat-nr2b9c
DK2894998T3 (da) Rotation af kegle
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
DK2838850T3 (da) Oprensning af titantetrachlorid
FR2995524B1 (fr) Prothese endo-urinaire
DK2916922T3 (da) Behandling af alkalisk bauxitrest
DK2825636T3 (da) Behandling af sædceller
SMT201700011B (it) Stent
FR2994506B1 (fr) Adaptation de transistors
ES1077799Y (es) Implante magnetico
DE102012001057A8 (de) Bauteil
DK2820042T3 (da) Igg-stimuleret remyelinisering af perifere nerver
DK3473276T3 (da) Teknikker til behandling af abscesser